Affimed Therapeutics (AFMD): שווי כולל של נכסי החברה

This chart illustrates the total assets of Affimed (AFMD), which stand at 0.00. Affimed (AFMD) delegates drug production to European contractors to optimize costs. The stability of the R&D department is sustained by the commitment of leading scientists and the targeted hiring of strategists. This strengthens the company's leadership position in NK-therapy, where the primary drivers are the drug Acimtamig and an innovative method of immune stimulation.

Investors view Affimed (AFMD) as a promising asset, where the dynamics of total assets—reverse-calculated via ROA to filter out market noise—reflect the efficiency of capital and liability management; by analyzing the trajectory of all company resources, one can understand how licensing contracts with pharma behemoths convert into a material base, which defines the status of this security as a high-tech biotechnological instrument.